Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF-targeted therapy in non-melanomatous BRAF-mutant tumours: a systematic review of broad but histology-modulated efficacy.

International journal of clinical oncology - 1 Aug 2026

Lefkovits Yael R, McLean Luke S, Middleton Mark R, Thomas David M

Abstract excerpt

BACKGROUND: Tumour agnostic therapies represent a paradigm shift in oncology. BRAF inhibitors have demonstrated efficacy in melanoma. However, their role in non-melanomatous cancers was originally contentious. This systematic review aims to evaluate the safety and efficacy of BRAF-targeted therapies, both as monotherapy and in combination with other targeted therapies, in BRAF-mutated, non-melanomatous tumours....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to BRAF gene

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Mutation

Share to Neoplasms

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 42277540
DOI: 10.1007/s10147-026-03079-y
PMCID: PMC13401532

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 16 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF-targeted therapy in non-melanomatous BRAF-mutant tumours: a systematic review of broad but histology-modulated efficacy.PMID 42277540Read ↗

Clinical Activity of Mitogen-Activated Protein Kinase–Targeted Therapies in Patients With Non–V600 BRAF-Mutant TumorsSemantic proximity Read ↗

Clinical activity of MAPK targeted therapies in patients with non-V600 BRAF mutant tumorsSemantic proximity Read ↗

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors.Semantic proximity Read ↗

Defining and Targeting BRAF Mutations in Solid Tumors.Semantic proximity Read ↗

[Expert consensus on BRAF inhibitors in the treatment of malignant solid tumors (2024 edition)].Semantic proximity Read ↗

Pan-Cancer Efficacy of Vemurafenib in BRAF V600-Mutant Non-Melanoma CancersSemantic proximity Read ↗

BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma.Semantic proximity Read ↗

Toxicities from BRAF and MEK Inhibitors: Strategies to Maximize Therapeutic Success.Semantic proximity Read ↗

BRAF Targeting Across Solid Tumors: Molecular Aspects and Clinical ApplicationsSemantic proximity Read ↗

Targeted therapy in BRAF‑mutant melanoma: Advances and challenges (Review).Semantic proximity Read ↗

BRAF Inhibitors and MelanomaSemantic proximity Read ↗

Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLCSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.